Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Vegetarian Diets for Weight Loss

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Cachexia and Cancer

Circadian Rhythm and Weight Loss

Mental Health Disorders, Weight Gain, and Exercise

Who Should Take Weight Loss Injections, and Who Shouldn’t?

How Does Semaglutide Work to Lose Weight?

Unexplained Weight Loss: When It Might Signal a Health Problem

See more featured articles »

Semaglutide and Weight Loss in Menopause

Weight Loss After Bariatric Surgery

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

How Oral GLP-1 Drugs Work For Weight Loss

Wegovy: A Breakthrough in Weight Loss?

Cachexia / Wasting Syndrome

Military Diet: Health Risks

The Natural Molecule That Could Rival Ozempic

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Does Cinnamon Help with Weight Loss?

Latest Weight Loss News and Research

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Overall dietary patterns matter more for heart health than nutrients

A healthy, balanced dietary pattern, rather than one focused on individual nutrients or foods is key to maintaining heart health, according to a Scientific Statement issued by the American College of Cardiology and published in JACC, its flagship journal.

30 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

University of Liverpool study tracks long-term impact of non-nutritive sweetened soft drinks

Researchers at the University of Liverpool have conducted the longest and most comprehensive randomized controlled trial on non-nutritive sweetened (NNS) soft drinks.

29 Sep 2026

Can’t stop thinking about food? You’re far from alone

Investigating 'food noise', this study reveals its association with diet quality and mental health, emphasizing demographic influences and eating behaviors.

29 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Kangaroo care helps smaller babies. Now researchers are studying babies born at normal weight

Researchers examine whether extending SSC beyond the first hour can improve early weight changes, breastfeeding and other maternal and newborn outcomes in normal-birthweight infants.

27 Sep 2026

GLP-1s linked to nutritional deficiencies in children

Children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes are at risk for nutritional deficiencies – diagnosed in nearly one in six patients (16.8%) within the first year – according to a new study published in the journal Childhood Obesity.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Experimental RNA therapy enhances weight loss while preserving lean muscle

GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight - primarily as fat.

21 Sep 2026

GLP-1 medications place children at risk for nutritional deficiencies

21 Sep 2026

HIV awareness emphasizes prevention, treatment and healthy aging

About 1.2 million people in the United States are living with HIV, or human immunodeficiency virus. Because of major advances in medical treatment and technology, people with HIV are living long, healthy lives.

18 Sep 2026

Social media influencers drive food misinformation across Europe

Scrolling through social media can mean encountering a supplement promising better health, a drink offering quick weight loss or a food promoted as a "superfood".

18 Sep 2026

Time-restricted eating may slow early-stage Huntington's disease

A simple change in when people eat may offer a promising new approach for Huntington's disease, according to research led by Oregon Health & Science University.

17 Sep 2026

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that causes excess fat to build up in the liver, affecting about one-quarter of adults worldwide.

17 Sep 2026

Experts call for eating-disorder screening before GLP-1 treatment

An international multidisciplinary panel developed consensus-based recommendations for GLP-1 receptor agonist use in people with eating disorders, calling for screening, individualized monitoring, patient education, and further research into safety and potential therapeutic effects. The experts cautioned that current evidence remains limited and inconsistent, particularly outside binge eating disorder, and identified major gaps in understanding the risk of new or recurrent eating disorders during treatment.

16 Sep 2026